These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 18837828)

  • 21. A mathematical model of hepatitis a transmission in the United States indicates value of universal childhood immunization.
    Van Effelterre TP; Zink TK; Hoet BJ; Hausdorff WP; Rosenthal P
    Clin Infect Dis; 2006 Jul; 43(2):158-64. PubMed ID: 16779741
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changing epidemiology of hepatitis A in Brazil: reassessing immunization policy.
    Vitral CL; Souto FJ; Gaspar AM
    J Viral Hepat; 2008 Oct; 15 Suppl 2():22-5. PubMed ID: 18837829
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Elimination of hepatitis a infection outbreaks in day care and school settings in southern Israel after introduction of the national universal toddler hepatitis a immunization program.
    Belmaker I; Dukhan L; Yosef Y; Leventhal A; Dagan R
    Pediatr Infect Dis J; 2007 Jan; 26(1):36-40. PubMed ID: 17195703
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatitis A: disease burden and current childhood vaccination strategies in the United States.
    Koslap-Petraco MB; Shub M; Judelsohn R
    J Pediatr Health Care; 2008; 22(1):3-11. PubMed ID: 18174084
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of universal hepatitis A immunization of children in Minsk City, Belarus: four-year follow-up.
    Fisenka EG; Germanovich FA; Glinskaya IN; Lyabis OI; Rasuli AM
    J Viral Hepat; 2008 Oct; 15 Suppl 2():57-61. PubMed ID: 18837836
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A dynamic model for assessing universal Hepatitis A vaccination in Canada.
    Bauch CT; Rao AS; Pham BZ; Krahn M; Gilca V; Duval B; Chen MH; Tricco AC
    Vaccine; 2007 Feb; 25(10):1719-26. PubMed ID: 17229493
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Introduction of routine hepatitis A immunization in Israel--the first in the world].
    Anis E; Leventhal A; Roitman M; Slater PE
    Harefuah; 2000 Feb; 138(3):177-80, 272. PubMed ID: 10883087
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatitis A vaccines.
    Shahidah KN
    Med J Malaysia; 2005 Jul; 60 Suppl B():112-5. PubMed ID: 16108190
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The cost-effectiveness of using hepatitis A/B combined vaccine versus hepatitis B vaccine alone for high-risk heterosexuals.
    Rein DB; Weinbaum CM
    Vaccine; 2008 Oct; 26(42):5331-3. PubMed ID: 18706957
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High prevalence of hepatitis A virus antibody among Bangladeshi children and young adults warrants pre-immunization screening of antibody in HAV vaccination strategy.
    Ahmed M; Munshi SU; Nessa A; Ullah MS; Tabassum S; Islam MN
    Indian J Med Microbiol; 2009; 27(1):48-50. PubMed ID: 19172060
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Should all children be immunised against hepatitis A?
    Temte JL
    BMJ; 2006 Mar; 332(7543):715-8. PubMed ID: 16565129
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatitis A in the era of vaccination.
    Wasley A; Fiore A; Bell BP
    Epidemiol Rev; 2006; 28():101-11. PubMed ID: 16775039
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epidemiology of hepatitis A before and after the introduction of a universal vaccination programme in Catalonia, Spain.
    Domínguez A; Oviedo M; Carmona G; Jansá JM; Borrás E; Salleras L; Plasència A
    J Viral Hepat; 2008 Oct; 15 Suppl 2():51-6. PubMed ID: 18837835
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Has the time come to control hepatitis A globally? Matching prevention to the changing epidemiology.
    Hendrickx G; Van Herck K; Vorsters A; Wiersma S; Shapiro C; Andrus JK; Ropero AM; Shouval D; Ward W; Van Damme P
    J Viral Hepat; 2008 Oct; 15 Suppl 2():1-15. PubMed ID: 18837827
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Public health control of hepatitis A: memorandum from a WHO meeting.
    Bull World Health Organ; 1995; 73(1):15-20. PubMed ID: 7704922
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness analysis of a cervical cancer vaccine in five Latin American countries.
    Colantonio L; Gómez JA; Demarteau N; Standaert B; Pichón-Rivière A; Augustovski F
    Vaccine; 2009 Sep; 27(40):5519-29. PubMed ID: 19616499
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of childhood hepatitis A vaccination in Argentina: a second dose is warranted.
    Ellis A; Rüttimann RW; Jacobs RJ; Meyerhoff AS; Innis BL
    Rev Panam Salud Publica; 2007 Jun; 21(6):345-56. PubMed ID: 17761046
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-benefit analysis of a rotavirus immunization program in the Arab Republic of Egypt.
    Ortega O; El-Sayed N; Sanders JW; Abd-Rabou Z; Antil L; Bresee J; Mansour A; Adib I; Nahkla I; Riddle MS
    J Infect Dis; 2009 Nov; 200 Suppl 1():S92-8. PubMed ID: 19817621
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Basis for vaccine recommendations].
    Lévy-Bruhl D
    Med Sci (Paris); 2007 Apr; 23(4):404-8. PubMed ID: 17433231
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Economic evaluations of hepatitis A vaccination in middle-income countries.
    Suwantika AA; Yegenoglu S; Riewpaiboon A; Tu HA; Postma MJ
    Expert Rev Vaccines; 2013 Dec; 12(12):1479-94. PubMed ID: 24168129
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.